In this context, we have tested the antitumoral potency of either resminostat, a novel oral HDACi,25 or MeV-super-cytosine deaminase (SCD), a prototypic suicide gene-armed measles vaccine virotherapeutic,11 in a commonly used panel of human hepatoma cell lines (HepG2, Hep3B, PLC/PRF/5). The gene discussed is SCD; the disease is hepatocellular carcinoma.